In type 2 diabetes with CKD and additional CV risk factors, sotagliflozin reduced total MACE vs. placebo at a median 14 mo. Thakkar A, Newby LK. Ann Intern Med 2025 Jun 3. doi: 10.7326/ANNALS-25-01791.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Thakkar A, Newby LK. In type 2 diabetes with CKD and additional CV risk factors, sotagliflozin reduced total MACE vs. placebo at a median 14 mo. Ann Intern Med 2025 Jun 3. doi: 10.7326/ANNALS-25-01791.
PMID: 40456154